IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科
学科主题临床医学
Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B
Li, Min-Ran; Xi, Hong-Li; Wang, Qin-Huan; Hou, Feng-Qin; Huo, Na; Zhang, Xia-Xia; Li, Fang; Xu, Xiao-Yuan
刊名PLOS ONE
2014-06-06
DOI10.1371/journal.pone.0098476
9期:6
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]CLOSED CIRCULAR DNA ; SURFACE-ANTIGEN ; LAMIVUDINE THERAPY ; ADEFOVIR DIPIVOXIL ; ANTIVIRAL AGENTS ; NATURAL-HISTORY ; ENTECAVIR ; REDUCTION ; VIRUS ; CCCDNA
英文摘要

Background & Aims: About 350-400 million people are infected with hepatitis B virus (HBV) chronically and 1 million people die of hepatitis B virus (HBV)-related liver diseases. Nucleos(t)ide analogues (NAs) have been used for the treatment against HBV. However, few studies have investigated the long-term effects of different nucleos(t)ide analogues on levels of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB). The aims of this study were to measure the magnitude of HBsAg reduction by long-term monotherapy with adefovir dipivoxil (ADV) and entecavir (ETV), to compare HBsAg reduction between the two drugs of different potency and to predict the expected time needed to achieve HBsAg loss.

Methods: We retrospectively evaluated the kinetics of HBsAg in 67 patients with CHB who all exhibited persistent viral suppression. These patients were treated with ADV or ETV for at least 6 years. HBV genotype was determined at baseline. Liver biochemistry, HBV serological markers, serum HBV DNA and HBsAg titers were determined at baseline, half year and yearly from year 1 to 6.

Results: Serum HBsAg titers after treatment with ADV or ETV were significantly lower than the baseline titers (P<0.05). HBsAg reduction rate of patients treated with ETV (0.11 log(10) IU/mL/year) was higher than that treated with ADV (0.10 log(10) IU/mL/year), and the calculated expected time to HBsAg loss for patients treated with ETV (approximate 24.99 years) was shorter than that with ADV (approximate 30.33 years), but there was no statistically significant difference between two groups (P>0.05).

Conclusion: Serum HBsAg titers gradually decreased during long-term treatment with either ADV or ETV. It appears that the potency of ADV on HBsAg reduction is close to that of ETV, as long as patients have achieved persistent viral suppression.

语种英语
WOS记录号WOS:000341869000033
项目编号2012ZX10002 003-004-003 ; 2013 ZX10002004-001-003 ; D121100003912003
资助机构12th Five-Year Plan ; Beijing Municipal Science and Technology Commission of major projects
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60704
专题北京大学第一临床医学院_感染疾病科
北京大学医学部管理机构_医学部
作者单位Peking Univ First Hosp, Dept Infect Dis, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Li, Min-Ran,Xi, Hong-Li,Wang, Qin-Huan,et al. Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B[J]. PLOS ONE,2014,9(6).
APA Li, Min-Ran.,Xi, Hong-Li.,Wang, Qin-Huan.,Hou, Feng-Qin.,Huo, Na.,...&Xu, Xiao-Yuan.(2014).Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B.PLOS ONE,9(6).
MLA Li, Min-Ran,et al."Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B".PLOS ONE 9.6(2014).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Min-Ran]的文章
[Xi, Hong-Li]的文章
[Wang, Qin-Huan]的文章
百度学术
百度学术中相似的文章
[Li, Min-Ran]的文章
[Xi, Hong-Li]的文章
[Wang, Qin-Huan]的文章
必应学术
必应学术中相似的文章
[Li, Min-Ran]的文章
[Xi, Hong-Li]的文章
[Wang, Qin-Huan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。